Table 2.
Cost-effectiveness of testing and treatment for HBV and HCV infection in 2016-2030 for the flatline, progress, and elimination scenario (present value, discounted).
| Program costs (USD 2016 millions) |
Future savings (USD 2016 millions) | Net incremental costs (USD 2016 millions) | Total incremental impact (DALYs) | ICER (2016 USD/DALY) | ||
|---|---|---|---|---|---|---|
| Commodities | Program and staff time | |||||
| HBV | ||||||
| Flatline∗ | 4434 | 3690 | 99 | 8025 | 9 947 682 | 807 |
| Progress† | 10 746 | 67 200 | 1347 | 76 600 | 143 900 928 | 532 |
| Elimination‡ | 19 091 | 165 737 | 1813 | 183 015 | 197 460 343 | 927 |
| Elimination versus progress§ | 8344 | 98 537 | 467 | 106 415 | 53 559 416 | 1987 |
| HCV | ||||||
| Flatline∗ | 1428 | 4519 | 6875 | −928 | 15 061 782 | −62 |
| Progress† | 3343 | 26 432 | 11 001 | 18 773 | 30 638 054 | 613 |
| Elimination‡ | 11 723 | 184 679 | 23 807 | 172 595 | 68 279 199 | 2528 |
| Elimination versus progress§ | 8380 | 158 247 | 12 806 | 153 821 | 37 641 146 | 4087 |
DALY indicates disability-adjusted life year; HBV, hepatitis B virus; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio;
Cost-effectiveness of treatment at the current level of testing and diagnosis compared with no action.
Cost-effectiveness of scaled up testing and treatment as per the progress scenario, compared with the flatline.
Cost-effectiveness of scaled up testing and treatment as per the elimination scenario, compared with the flatline.
Cost-effectiveness of scaled up testing and treatment as per the elimination scenario, compared with the progress scenario.